Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2013

Open Access 01-11-2013 | Meeting abstract

P01-009 – 2 years of colchicine IV in intractable FMF

Authors: L Kaly, N Boulman, D Rimar, G Slobodin, I Rosner, M Rozenbaum

Published in: Pediatric Rheumatology | Special Issue 1/2013

Login to get access

Excerpt

Oral colchicine therapy has been shown effective both in controlling the symptoms and preventing the development of amyloidosis in FMF. However, 5 to 10% of FMF patients are resistant to this conventional therapy. …
Metadata
Title
P01-009 – 2 years of colchicine IV in intractable FMF
Authors
L Kaly
N Boulman
D Rimar
G Slobodin
I Rosner
M Rozenbaum
Publication date
01-11-2013
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue Special Issue 1/2013
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/1546-0096-11-S1-A13

Other articles of this Special Issue 1/2013

Pediatric Rheumatology 1/2013 Go to the issue

Meeting abstract

P01-022 – MEFV gene mutations registered to infevers

Meeting abstract

P01-028 – MEFV mutation in Morrocan child wuth familial Mediterranean fever

Meeting abstract

P01-044 – Uncommon manifestations of familial Mediterranean

Meeting abstract

P03-021 - Characterization of BM-MSC from osteopetrotic mice

Meeting abstract

P01-003 – Bleeding disorder in FMF

Meeting abstract

PW01-024 – Phenotypic analysis of a MEFV negative FMF cohort